A humanized HLA-DR antibody (hu1D10, apolizumab) in combination with granulocyte colony-stimulating factor (filgrastim) for the treatment of non-Hodgkin's lymphoma: a pilot study - Wikidata - wikimedia - TriplyDB

A humanized HLA-DR antibody (hu1D10, apolizumab) in combination with granulocyte colony-stimulating factor (filgrastim) for the treatment of non-Hodgkin's lymphoma: a pilot study

A humanized HLA-DR antibody (hu1D10, apolizumab) in combination with granulocyte colony-stimulating factor (filgrastim) for the treatment of non-Hodgkin's lymphoma: a pilot study

http://www.wikidata.org/entity/Q28270899

about

Therapy of B-cell malignancies by anti-HLA-DR humanized monoclonal antibody, IMMU-114, is mediated through hyperactivation of ERK and JNK MAP kinase signaling pathways Preclinical studies on targeted delivery of multiple IFNα2b to HLA-DR in diverse hematologic cancers.Target Therapy in Hematological Malignances: New Monoclonal Antibodies.Use of antibodies and immunoconjugates for the therapy of more accessible cancers.

P2860

Q33944243-8723F50E-ADFD-4B3B-9F72-4D21F88B37DD Q35172476-218C52FD-4BF8-4CFE-8FD2-3159318C54D1 Q36979140-E9D46B42-8A62-453F-97FA-7FCAF0433C3E Q37174938-94D7FC21-05A6-49C8-9E0A-6CB79BB28BEE

P2860

A humanized HLA-DR antibody (hu1D10, apolizumab) in combination with granulocyte colony-stimulating factor (filgrastim) for the treatment of non-Hodgkin's lymphoma: a pilot study

http://www.wikidata.org/entity/Q28270899

description

2006 nî lūn-bûn

@nan

2006 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

A humanized HLA-DR antibody (h ...... gkin's lymphoma: a pilot study

@ast

A humanized HLA-DR antibody (h ...... gkin's lymphoma: a pilot study

@en

A humanized HLA-DR antibody (h ...... gkin's lymphoma: a pilot study

@nl

type

label

A humanized HLA-DR antibody (h ...... gkin's lymphoma: a pilot study

@ast

A humanized HLA-DR antibody (h ...... gkin's lymphoma: a pilot study

@en

A humanized HLA-DR antibody (h ...... gkin's lymphoma: a pilot study

@nl

prefLabel

A humanized HLA-DR antibody (h ...... gkin's lymphoma: a pilot study

@ast

A humanized HLA-DR antibody (h ...... gkin's lymphoma: a pilot study

@en

A humanized HLA-DR antibody (h ...... gkin's lymphoma: a pilot study

@nl

P1433

Q28270899-779ACEC3-18FF-407D-9285-ED1C79D921DC

P1476

Q28270899-2CB37BF8-ED24-4158-857D-B40DA88FEB58

P2093

Q28270899-1352D063-279A-4294-B35A-22C3A333BEF7

Q28270899-3CB6F010-94DC-4DB9-B99D-110F2722AD6F

Q28270899-43955FB0-7C88-4D90-9759-AE98885CC1F9

Q28270899-68B19CBD-2977-4BD7-9228-616978BF6D92

Q28270899-B4DEA1A4-4316-40E5-BA83-D1C52C4E8783

Q28270899-B98D0635-0E14-4905-8814-4441FF1FA158

Q28270899-BDFC30D0-95F4-4185-A807-CDA931EDBB17

P2860

Q28270899-141455B2-FDF7-45F3-AFE6-554013792BC1

Q28270899-19C161F0-016D-46C9-81EF-E25EAD1009EA

Q28270899-49DCB598-2CD8-4ED6-971A-26EB2241D22D

Q28270899-9C861F3A-2306-4CA3-92B7-9DF5804F26F0

Q28270899-BD9EF52E-82AB-429C-8FCA-BDE908555D6A

Q28270899-CD4CB55B-B900-43A2-A3ED-6DD8C205550A

Q28270899-D37947C7-FC91-4138-9372-33D34E8AF23F

Q28270899-EB3EF222-133E-447D-A03F-22C75D40213C

Q28270899-F23EFC3D-2C01-4861-AA57-EA2085B3687C

P304

Q28270899-EA007607-47D9-4B46-9F94-14609ABE2BC5

P31

Q28270899-06362E1C-0907-4416-A3DF-DC3303D12168

P356

Q28270899-04AD54BB-6D86-495E-BD6D-9D34290112E1

P407

Q28270899-9A2E5F36-7957-4E35-A2A7-6DAFEC009A3A

P433

Q28270899-7B01FE19-F220-4A2A-A486-25A08772A34E

P478

Q28270899-C56C9F40-20A3-4223-928F-F9404E483781

P50

Q28270899-7ED18025-632D-499A-9305-B6E8C54C7387

P577

Q28270899-F3725724-02FE-454F-AD9E-1FE1484A24B4

P698

Q28270899-C7DE236B-D00B-446C-9A5B-CB4ACD9025BB

P356

10428190600757944

P1433

Leukemia & Lymphoma

P1476

A humanized HLA-DR antibody (h ...... gkin's lymphoma: a pilot study

@en

P2093

Bernhard Stockmeyer

http://www.w3.org/2001/XMLSchema#string

Dorit Rech

http://www.w3.org/2001/XMLSchema#string

Juergen Rech

http://www.w3.org/2001/XMLSchema#string

Martin Gramatzki

http://www.w3.org/2001/XMLSchema#string

Michael Dechant

http://www.w3.org/2001/XMLSchema#string

Roland Repp

http://www.w3.org/2001/XMLSchema#string

Thomas Valerius

http://www.w3.org/2001/XMLSchema#string

P2860

Milestones in the development of Lym-1 therapy.

The intriguing role of polymorphonuclear neutrophils in antitumor reactions.

HLA class II antibodies in the treatment of hematologic malignancies.

Concurrent administration of granulocyte colony-stimulating factor or granulocyte-monocyte colony-stimulating factor enhances the biological activity of rituximab in a severe combined immunodeficiency mouse lymphoma model.

MHC class II signaling in B-cell activation.

Treatment of relapsed B-cell non-Hodgkin's lymphoma with a combination of chimeric anti-CD20 monoclonal antibodies (rituximab) and G-CSF: final report on safety and efficacy.

Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing.

Humanization and characterization of the anti-HLA-DR antibody 1D10.

In Vivo Pharmacodynamic Effects of Hu1D10 (Remitogen), a Humanized Antibody Reactive Against a Polymorphic Determinant of HLA-DR Expressed on B Cells

P304

2147-2154

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/10428190600757944

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

47

http://www.w3.org/2001/XMLSchema#string

P50

Gerald Niedobitek

P577

2006-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17071489

http://www.w3.org/2001/XMLSchema#string